Polycyclic ALK Inhibitor Overcoming Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ALK inhibitors, such as Crizotinib, face challenges with drug resistance, particularly due to mutations like L1196M, C1156Y, and F1174L, necessitating the development of second-generation inhibitors with enhanced therapeutic efficacy and improved physico-chemical properties to effectively target ALK-mediated cancers.
Innovation Solution
A polycyclic compound with specific structural modifications, as defined by Formula (I), is developed to serve as a potent ALK/ROS1 inhibitor, offering excellent inhibitory activity against drug-resistant mutations and improving bioavailability and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-generation ALK inhibitors like Crizotinib are used, then initial therapeutic effect is achieved, but drug resistance develops after 1-2 years of treatment
Solution Approach 1:
The patent modifies the chemical structure parameters of ALK inhibitors by introducing specific substituents (R1, R2, R3, R4, R5, R6 groups) at defined positions on the pyrimidine ring system. These structural parameter changes enable the compound to maintain binding affinity to ALK kinase even when resistance mutations (L1196M, C1156Y, F1174L) are present, thereby extending the duration of therapeutic effect beyond what first-generation inhibitors can achieve.
Solution Approach 2:
The patent creates composite molecular structures combining multiple functional groups (pyrimidine core, substituted aromatic rings, heterocyclic moieties) into a single inhibitor molecule. This composite structure allows simultaneous interaction with multiple residues in the ALK binding pocket, providing robust inhibition that overcomes resistance mechanisms that would affect simpler inhibitor structures.
2Reliability
If ALK inhibitor structure is modified to overcome resistance mutations, then inhibitory activity against resistant mutations is improved, but physico-chemical properties and bioavailability may be affected
Solution Approach 1:
The patent carefully selects and optimizes the physico-chemical parameters of the inhibitor molecules by controlling the nature and position of substituents (R1-R6 groups). This includes adjusting molecular weight, lipophilicity, and hydrogen bonding capacity to ensure optimal oral bioavailability and metabolic stability while maintaining high inhibitory activity against ALK and its resistant variants.
Solution Approach 2:
The patent introduces specific functional groups at localized positions on the inhibitor molecule (specific R groups at defined positions) that provide targeted interactions with resistance mutations. These local modifications enhance binding to mutant ALK forms without compromising the overall molecular properties required for good bioavailability and pharmacokinetic behavior.
Data Source
AI summary
Provided is a polycyclic inhibitor of anaplastic lymphoma kinase as represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, and ring A are as defined in the description. The invention also relates to a method for preparing the compound, a pharmaceutical preparation and a pharmaceutical composition comprising the compound, and use of the compound, the pharmaceutically acceptable salt or stereoisomer thereof in manufacture of a medicament for the treatment and/or prevention of an anaplastic lymphoma kinase-mediated cancer or non-cancer related diseases.